Evidence map›Paper›PMID 15722318›Full record

ArticleThe British journal of ophthalmology2005

Plasmacellular differentiation in extranodal marginal zone B cell lymphomas of the ocular adnexa: an analysis of the neoplastic plasma cell phenotype and its prognostic significance in 136 cases.

S E Coupland, M Hellmich, C Auw-Haedrich, W R Lee, I Anagnostopoulos, H Stein

Open access · bronzeAbstract read
In one paragraph

Article in The British journal of ophthalmology, 2005. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed
2.5field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 47 citations in OpenAlex.

  1. Article
  2. Article
  3. Conjunctival Lymphoma.Eye (London, England) · 2023
    Review
  4. Ectopic lymphoid structures in the aged lacrimal glands.Clinical immunology (Orlando, Fla.) · 2023
    Article
  5. Article
  6. Review
  7. Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Review
  14. Ocular adnexal marginal zone B cell lymphoma: a clinical and pathologic study of 23 cases.Virchows Archiv : an international journal of pathology · 2006
    Article
  15. Article
  16. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 2 countries.

S E CouplandDepartment of Pathology, Charité-Medical Faculty Berlin, Campus Benjamin Franklin, Hindenburgdamm 30, D-12203 Berlin, Germany. sarah.coupland@charite.de
M Hellmich
C Auw-Haedrich
W R Lee
I Anagnostopoulos
H Stein
Charité - Universitätsmedizin Berlin · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

aimTo determine (a) the expression of plasma cell related antigens in extranodal marginal zone B cell lymphomas (EMZL) of the ocular adnexa; and (b) the prognostic value of plasmacellular differentiation in these tumours.

methodsA consecutive case series of 136 ocular adnexal EMZL obtained from three ocular pathology centres over 20 years was analysed retrospectively. An extensive immunohistochemical panel, including the plasma cell related antigens VS38c, CD38, CD138, multiple myeloma oncogene-1-protein (MUM1/IRF4), and CREB binding protein (CBP) was performed. EMZL were defined as "plasmacellular differentiated" on the basis of morphological features, evidence of cytoplasmic immunoglobulin, negativity for BSAP/PAX5, and expression of at least one of the investigated plasma cell related antigens. Controls included normal or hyperplastic lymphatic tissues. Detailed clinical data were collected for most patients, and compared with the results of immunohistochemistry. The end points considered for statistical analysis were development of local tumour recurrence, development of systemic disease, and lymphoma related death.

results57 (42%) of the 136 ocular adnexal EMZL showed a plasmacellular differentiation; 45 of these plasmacytoid cases were primary tumours. In contrast with most admixed normal plasma cells, which displayed co-expression of MUM1/IRF4, Vs38c, CD38, CD138, and CBP, the plasmacellular differentiated EMZL tumour cells demonstrated co-expression of all five plasma cell related antigens in only six of 57 (11%) plasmacellular differentiated ocular adnexal EMZL. The most commonly expressed plasma cell related antigen was MUM1/IRF4, immunoreactivity being seen in 56/57 (98%) plasmacellular differentiated EMZL examined. Although the association of plasmacellular differentiation in primary ocular adnexal EMZL and disseminated disease was statistically significant on univariate analysis (p = 0.042), this was weaker on multivariate analysis.

conclusionPlasmacellular differentiated tumour cells in EMZL demonstrate an aberrant immune profile for plasma cell related antigens when compared with normal plasma cells. On multivariate analysis, plasmacellular differentiation in ocular adnexal EMZL was not significantly associated with local recurrence, the development of systemic disease, or with lymphoma related death.

Indexed as

ADP-ribosyl CyclaseADP-ribosyl Cyclase 1AgedAntibodies, MonoclonalAntigens, CDAutoantigensBiomarkers, TumorCase-Control StudiesCell DifferentiationCREB-Binding ProteinDNA-Binding ProteinsEye NeoplasmsFemaleHumansImmunohistochemistryInterferon Regulatory Factor-4ADP-ribosyl CyclaseADP-ribosyl Cyclase 1Antibodies, MonoclonalAntigens, CDAutoantigensBiomarkers, TumorCD38 protein, humanCREB-Binding ProteinCREBBP protein, humanDNA-Binding ProteinsInterferon Regulatory Factor-4Interferon Regulatory FactorsMembrane GlycoproteinsNuclear ProteinsProteoglycansSDC1 protein, humanSyndecan-1SyndecansTrans-ActivatorsTranscription FactorsVS38 monoclonal antibody

Identifiers

PMID15722318
PMCPMC1772544
OpenAlexW2090310721

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.